21智讯01月12日电，重药控股发布2025年前三季度权益分派实施公告，公司以享有利润分配权的股本总 数为基数，向全体股东每10股派0.30元人民币现金（含税），不送红股，不以公积金转增股本。本次权 益分派股权登记日为2026年1月15日，除权除息日为2026年1月16日。公司此次委托中国结算深圳分公司 代派的A股股东现金红利将于2026年1月16日通过股东托管证券公司（或其他托管机构）直接划入其资 金账户。 ...

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]

Group 1: Dividend Indices - The Low Volatility Dividend Index (H30269.CSI) selects 50 securities with good liquidity, continuous dividends, moderate payout ratios, positive growth in dividends per share, high dividend yields, and low volatility, with a dividend yield of 4.46% as of January 9 [1] - The Quality Dividend Index (931468.CSI) selects 50 listed companies with continuous cash dividends, high payout ratios, and strong profitability, with a dividend yield of 3.50% as of January 9 [1] - The Low Volatility Dividend ETF (159547) is the ETF with the lowest comprehensive fee tracking the Low Volatility Dividend Index, with quarterly assessments for dividends [1] Group 2: Company Dividend Announcements - Heavy Pharmaceutical Holdings announced a cash dividend of RMB 0.30 per 10 shares (tax included), with the record date on January 15, 2026, and the ex-dividend date on January 16, 2026 [1] - Fuling Zhacai announced a cash dividend of RMB 2.00 per 10 shares (tax included), with the record date on January 15, 2026, and the ex-dividend date on January 16, 2026 [2] - China Merchants Bank announced a cash dividend of RMB 1.013 per share (tax included), with the record date on January 15, 2026, and the ex-dividend date on January 16, 2026 [2]

证券代码：000950 证券简称：重药控股 公告编号：2026-002 重药控股股份有限公司 2025 年前三季度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示：重药控股股份有限公司（以下简称"公司"）通过公司回购专用证 券账户持有公司股份 15,406,600 股，该部分股份不享有利润分配权利，本次权益 分派实施后，除权除息参考价如下： 一、股东会审议通过利润分配方案的情况 1.公司于 2025 年 12 月 22 日召开 2025 年第五次临时股东会审议通过了《2025 年前三季度利润分配预案的议案》，2025 年前三季度利润分配方案的具体内容 为：以 2025 年 9 月 30 日享有利润分配权的股本总数 1,712,778,096 股（总股本 1,728,184,696 股扣除公司回购专户中持有的股份 15,406,600 股）为基数，向全体 股东每 10 股派发 0.30 元人民币现金（含税），分配总金额为 51,383,342.88 元 （含税），不送红股，不以公积金转增股本。如在分配预案披露之日至实施权益 分配股权登记 ...

Market Performance - The pharmaceutical commercial sector increased by 1.32% on January 9, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] Top Gainers - RunDa Medical (603108) closed at 17.94, up 9.99% with a trading volume of 846,200 shares [1] - Huaren Health (301408) closed at 22.17, up 9.97% with a trading volume of 627,800 shares [1] - Shangyu Pingmin (301017) closed at 17.24, up 7.75% with a trading volume of 336,500 shares [1] Other Notable Stocks - Zhongyao Holdings (000950) closed at 6.31, up 5.87% with a trading volume of 1,147,000 shares [1] - Saily Medical (603716) closed at 27.83, up 4.39% with a trading volume of 783,100 shares [1] Market Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 122 million yuan from institutional investors and 174 million yuan from speculative funds, while retail investors saw a net inflow of 296 million yuan [2] - The trading volume and turnover for various stocks indicate a mixed sentiment among different investor categories [2] Individual Stock Fund Flow - RunDa Medical had a net inflow of 2.30 billion yuan from institutional investors, while it faced a net outflow of 1.36 billion yuan from speculative funds [3] - Zhongyao Holdings saw a net inflow of 61.04 million yuan from institutional investors, with a net outflow of 62.93 million yuan from retail investors [3] - The overall fund flow indicates varying levels of confidence among different investor types in the pharmaceutical sector [3]

Group 1 - The core viewpoint of the news is that Chongqing Pharmaceutical Holdings has shown a significant increase in stock price and positive financial performance indicators, indicating potential growth in the pharmaceutical distribution sector [1][2]. Group 2 - As of January 9, the stock price of Chongqing Pharmaceutical Holdings rose by 4.36% to 6.22 CNY per share, with a total market capitalization of 10.749 billion CNY [1]. - The company has seen a year-to-date stock price increase of 6.87%, with a 20-day increase of 6.14% and a 60-day increase of 18.70% [1]. - The main business revenue composition includes 81.74% from pharmaceuticals, 16.71% from medical devices, and 1.54% from other sources [1]. Group 3 - For the period from January to September 2025, Chongqing Pharmaceutical Holdings achieved a revenue of 62.211 billion CNY, representing a year-on-year growth of 4.22%, while the net profit attributable to shareholders increased by 31.41% to 384 million CNY [2]. - The company has distributed a total of 864 million CNY in dividends since its A-share listing, with 294 million CNY distributed in the last three years [3]. Group 4 - As of September 30, 2025, the number of shareholders for Chongqing Pharmaceutical Holdings decreased by 4.05% to 42,000, while the average circulating shares per person increased by 4.22% to 41,112 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 10.091 million shares, an increase of 851,000 shares compared to the previous period [3].

《CollaborationandLicenseAgreement》("许可协议")，其中主要包括由药友制药就口服小分子胰高血糖 素样肽-1受体(GLP-1R)激动剂(包括YP05002)及含有该活性成分的产品授予辉瑞于许可区域(即全球范围) 及领域(人类、动物所有适应症的治疗、诊断及预防)独家开发、使用、生产及商业化权利。截至目前， 药友制药已收到辉瑞支付的首付款15000万美元。 证券日报网讯1月8日，重药控股（000950）在互动平台回答投资者提问时表示，2025年12月9日，公司 参股子公司药友制药与上海复星医药（600196）产业发展有限公司及辉瑞共同签订 ...

重药控股公告称，公司于2025年7月通过回购股份议案，拟斥资8000万-1亿元、以不超6.6元/股的价格回 购股份用于减资，回购期限12个月。截至2025年12月31日，公司累计回购股份1540.66万股，约占总股 本的0.8915%，最高成交价5.48元/股，最低成交价5.01元/股，支付总金额8099.88万元（不含交易费 用），本次回购符合相关规定。后续将按计划继续实施回购并及时披露。 ...

证券代码：000950 证券简称：重药控股 公告编号：2026-001 重药控股股份有限公司 关于回购股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、截至上月末回购股份的进展情况 截至 2025 年 12 月 31 日，公司通过股份回购专用证券账户以集中竞价交易 方式累计回购股份数量为 15,406,600 股，约占公司总股本的 0.8915%；最高成交 价为 5.48 元/股、最低成交价为 5.01 元/股，支付总金额为 80,998,765.98 元（不 含交易费用）。本次回购符合法律法规、规范性文件的有关规定及公司回购股份 方案的要求。 二、其他说明 公司回购股份的时间、回购股份价格及集中竞价交易的委托时段符合《深圳 证券交易所上市公司自律监管指引第 9 号——回购股份》的相关规定，具体情况 如下： 1.公司未在下列期间回购公司股份： （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； （2）中国证监会和深圳证券交易所规定的其他情形。 2.公司以集中竞价交易方式回购股份符合 ...

Group 1 - The company emphasizes the importance of data governance and has established a specialized data management team [1] - The company is building an enterprise data middle platform to enhance data quality and security [1] - These initiatives are aimed at providing a solid foundation for the company's digital transformation and upgrade [1]